Key roles of hyaluronan and its CD44 receptor in the stemness and survival of cancer stem cells

Frontiers in Oncology

Volumn 5, Issue Aug, 2015, Pages

  Chanmee, Theerawut ^a   Ontong, Pawared ^a   Kimata, Koji ^b   Itano, Naoki ^a  

^a KYOTO SANGYO UNIVERSITY   (Japan)

^b AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cancer stem cell; CD44; Epithelial to mesenchymal transition; Hyaluronan; Multidrug resistance

Indexed keywords

CASPASE 3; CASPASE 9; CD44V ANTIGEN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLUTATHIONE; HYALURONIC ACID; KERATINOCYTE GROWTH FACTOR; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN BAK; PROTEIN BCL XL; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VIMENTIN;

ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; CANCER STEM CELL; CELL SURVIVAL; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG METASTASIS; LYMPHANGIOGENESIS; MULTIDRUG RESISTANCE; OVARY CARCINOMA; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; UPREGULATION;

EID: 84940988452     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00180     Document Type: Review

References (99)

1. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 12(11):767-75. doi: 10.1038/nrc3368.
2. Alison MR, Lin WR, Lim SM, Nicholson LJ. Cancer stem cells: in the line of fire. Cancer Treat Rev (2012) 38(6):589-98. doi:10.1016/j.ctrv.2012.03.003.
3. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell (2014) 14(3):275-91. doi:10.1016/j.stem.2014.02.006.
4. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 133(4):704-15. doi:10.1016/j.cell.2008.03.027.
5. Munoz P, Iliou MS, Esteller M. Epigenetic alterations involved in cancer stem cell reprogramming. Mol Oncol (2012) 6(6):620-36. doi:10.1016/j.molonc.2012.10.006.
6. Li Y, Laterra J. Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res (2012) 72(3):576-80. doi:10.1158/0008-5472.CAN-11-3070.
7. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer (2011) 11(4):254-67. doi:10.1038/nrc3023.
8. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A (2007) 104(24):10158-63. doi:10.1073/pnas.0703478104.
9. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res (2005) 65(23):10946-51. doi:10.1158/0008-5472.CAN-05-2018.
10. Hirata K, Suzuki H, Imaeda H, Matsuzaki J, Tsugawa H, Nagano O, et al. CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br J Cancer (2013) 109(2):379-86. doi:10.1038/bjc.2013.314.
11. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A (2007) 104(3):973-8. doi:10.1073/pnas.0610117104.
12. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells (2009) 27(5):1006-20. doi:10.1002/stem.30.
13. Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One (2010) 5(11):e14062. doi:10.1371/journal.pone.0014062.
14. Han J, Fujisawa T, Husain SR, Puri RK. Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma. BMC Cancer (2014) 14:173. doi:10.1186/1471-2407-14-173.
15. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 100(7):3983-8. doi:10.1073/pnas.0530291100.
16. Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer (2011) 104(11):1730-8. doi:10.1038/bjc.2011.159.
17. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res (2007) 67(3):1030-7. doi:10.1158/0008-5472.CAN-06-2030.
18. Bourguignon LY, Wong G, Earle C, Chen L. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem (2012) 287(39):32800-24. doi:10.1074/jbc.M111.308528.
19. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A (2009) 106(33):14016-21. doi:10.1073/pnas.0906549106.
20. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 68(11):4311-20. doi:10.1158/0008-5472.CAN-08-0364.
21. Wang P, Gao Q, Suo Z, Munthe E, Solberg S, Ma L, et al. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. PLoS One (2013) 8(3):e57020. doi:10.1371/journal.pone.0057020.
22. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell (2008) 13(2):153-66. doi:10.1016/j.ccr.2008.01.013.
23. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 3(7):730-7. doi:10.1038/nm0797-730.
24. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature (2004) 432(7015):396-401. doi:10.1038/nature03128.
25. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2007) 445(7123):106-10. doi:10.1038/nature05372.
26. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, et al. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer (2008) 18(3):506-14. doi:10.1111/j.1525-1438.2007.01056.x.
27. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ (2008) 15(3):504-14. doi:10.1038/sj.cdd.4402283.
28. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer (2007) 43(5):935-46. doi:10.1016/j.ejca.2007.01.017.
29. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature (2008) 451(7176):345-9. doi:10.1038/nature06489.
30. Toole BP. Hyaluronan in morphogenesis. Semin Cell Dev Biol (2001) 12(2):79-87. doi:10.1006/scdb.2000.0244.
31. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer (2004) 4(7):528-39. doi:10.1038/nrc1391.
32. Itano N, Sawai T, Yoshida M, Lenas P, Yamada Y, Imagawa M, et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem (1999) 274(35):25085-92. doi:10.1074/jbc.274.35.25085.
33. Thorne RF, Legg JW, Isacke CM. The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. J Cell Sci (2004) 117(Pt 3):373-80. doi:10.1242/jcs.00954.
34. Hathcock KS, Hirano H, Murakami S, Hodes RJ. CD44 expression on activated B cells. Differential capacity for CD44-dependent binding to hyaluronic acid. J Immunol (1993) 151(12):6712-22.
35. Skelton TP, Zeng C, Nocks A, Stamenkovic I. Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. J Cell Biol (1998) 140(2):431-46. doi:10.1083/jcb.140.2.431.
36. Nagano O, Okazaki S, Saya H. Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene (2013) 32(44):5191-8. doi:10.1038/onc.2012.638.
37. Anttila MA, Tammi RH, Tammi MI, Syrjanen KJ, Saarikoski SV, Kosma VM. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res (2000) 60(1):150-5.
38. Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol (2000) 156(2):529-36. doi:10.1016/S0002-9440(10)64757-8.
39. Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, Lipponen P, et al. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res (1998) 58(2):342-7.
40. Koyama H, Hibi T, Isogai Z, Yoneda M, Fujimori M, Amano J, et al. Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am J Pathol (2007) 170(3):1086-99. doi:10.2353/ajpath.2007.060793.
41. Auvinen P, Rilla K, Tumelius R, Tammi M, Sironen R, Soini Y, et al. Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival. Breast Cancer Res Treat (2014) 143(2):277-86. doi:10.1007/s10549-013-2804-7.
42. Udabage L, Brownlee GR, Nilsson SK, Brown TJ. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res (2005) 310(1):205-17. doi:10.1016/j.yexcr.2005.07.026.
43. Itano N, Sawai T, Miyaishi O, Kimata K. Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells. Cancer Res (1999) 59(10):2499-504.
44. Kosaki R, Watanabe K, Yamaguchi Y. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res (1999) 59(5):1141-5.
45. Liu N, Gao F, Han Z, Xu X, Underhill CB, Zhang L. Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. Cancer Res (2001) 61(13):5207-14.
46. Udabage L, Brownlee GR, Waltham M, Blick T, Walker EC, Heldin P, et al. Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res (2005) 65(14):6139-50. doi:10.1158/0008-5472.CAN-04-1622.
47. Kobayashi N, Miyoshi S, Mikami T, Koyama H, Kitazawa M, Takeoka M, et al. Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascularization. Cancer Res (2010) 70(18):7073-83. doi:10.1158/0008-5472.CAN-09-4687.
48. de la Motte CA, Hascall VC, Drazba J, Bandyopadhyay SK, Strong SA. Mononuclear leukocytes bind to specific hyaluronan structures on colon mucosal smooth muscle cells treated with polyinosinic acid:polycytidylic acid: inter-alpha-trypsin inhibitor is crucial to structure and function. Am J Pathol (2003) 163(1):121-33. doi:10.1016/S0002-9440(10)63636-X.
49. Ribatti D, Nico B, Crivellato E, Vacca A. Macrophages and tumor angiogenesis. Leukemia (2007) 21(10):2085-9. doi:10.1038/sj.leu.2404900.
50. Schmaus A, Klusmeier S, Rothley M, Dimmler A, Sipos B, Faller G, et al. Accumulation of small hyaluronan oligosaccharides in tumour interstitial fluid correlates with lymphatic invasion and lymph node metastasis. Br J Cancer (2014) 111(3):559-67. doi:10.1038/bjc.2014.332.
51. Kumar S, West DC, Ponting JM, Gattamaneni HR. Sera of children with renal tumours contain low-molecular-mass hyaluronic acid. Int J Cancer (1989) 44(3):445-8. doi:10.1002/ijc.2910440311.
52. Lokeshwar VB, Rubinowicz D, Schroeder GL, Forgacs E, Minna JD, Block NL, et al. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem (2001) 276(15):11922-32. doi:10.1074/jbc.M008432200.
53. West DC, Hampson IN, Arnold F, Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science (1985) 228(4705):1324-6. doi:10.1126/science.2408340.
54. Takahashi Y, Li L, Kamiryo M, Asteriou T, Moustakas A, Yamashita H, et al. Hyaluronan fragments induce endothelial cell differentiation in a CD44-and CXCL1/GRO1-dependent manner. J Biol Chem (2005) 280(25):24195-204. doi:10.1074/jbc.M411913200.
55. Nakamura K, Yokohama S, Yoneda M, Okamoto S, Tamaki Y, Ito T, et al. High, but not low, molecular weight hyaluronan prevents T-cell-mediated liver injury by reducing proinflammatory cytokines in mice. J Gastroenterol (2004) 39(4):346-54. doi:10.1007/s00535-003-1301-x.
56. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, et al. Regulation of lung injury and repair by toll-like receptors and hyaluronan. Nat Med (2005) 11(11):1173-9. doi:10.1038/nm1315.
57. Ghatak S, Misra S, Toole BP. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem (2002) 277(41):38013-20. doi:10.1074/jbc.M202404200.
58. Subramaniam V, Vincent IR, Gilakjan M, Jothy S. Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy. Exp Mol Pathol (2007) 83(3):332-40. doi:10.1016/j.yexmp.2007.08.013.
59. Ichikawa W. Positive relationship between expression of CD44 and hepatic metastases in colorectal cancer. Pathobiology (1994) 62(4):172-9. doi:10.1159/000163907.
60. Mulder JW, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet (1994) 344(8935):1470-2. doi:10.1016/S0140-6736(94)90290-9.
61. Nihei Z, Ichikawa W, Kojima K, Togo S, Miyanaga T, Hirayama R, et al. The positive relationship between the expression of CD44 variant 6 and prognosis in colorectal cancer. Surg Today (1996) 26(9):760-1. doi:10.1007/BF00312104.
62. Marangoni E, Lecomte N, Durand L, de Pinieux G, Decaudin D, Chomienne C, et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer (2009) 100(6):918-22. doi:10.1038/sj.bjc.6604953.
63. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res (1993) 53(20):4754-6.
64. Wang SJ, Wreesmann VB, Bourguignon LY. Association of CD44 V3-containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer. Head Neck (2007) 29(6):550-8. doi:10.1002/hed.20544.
65. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell (1991) 65(1):13-24. doi:10.1016/0092-8674(91)90403-L.
66. Zoltan-Jones A, Huang L, Ghatak S, Toole BP. Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem (2003) 278(46):45801-10. doi:10.1074/jbc.M308168200.
67. Li Y, Heldin P. Hyaluronan production increases the malignant properties of mesothelioma cells. Br J Cancer (2001) 85(4):600-7. doi:10.1054/bjoc.2001.1922.
68. Camenisch TD, Spicer AP, Brehm-Gibson T, Biesterfeldt J, Augustine ML, Calabro A Jr, et al. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J Clin Invest (2000) 106(3):349-60. doi:10.1172/JCI10272.
69. Chanmee T, Ontong P, Mochizuki N, Kongtawelert P, Konno K, Itano N. Excessive hyaluronan production promotes acquisition of cancer stem cell signatures through the coordinated regulation of twist and the transforming growth factor beta (TGF-beta)-snail signaling axis. J Biol Chem (2014) 289(38):26038-56. doi:10.1074/jbc.M114.564120.
70. El-Haibi CP, Bell GW, Zhang J, Collmann AY, Wood D, Scherber CM, et al. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A (2012) 109(43):17460-5. doi:10.1073/pnas.1206653109.
71. Porsch H, Bernert B, Mehic M, Theocharis AD, Heldin CH, Heldin P. Efficient TGFbeta-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2. Oncogene (2013) 32(37):4355-65. doi:10.1038/onc.2012.475.
72. Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, et al. Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther (2011) 10(1):169-77. doi:10.1158/1535-7163.MCT-10-0544.
73. Qu C, Rilla K, Tammi R, Tammi M, Kroger H, Lammi MJ. Extensive CD44-dependent hyaluronan coats on human bone marrow-derived mesenchymal stem cells produced by hyaluronan synthases HAS1, HAS2 and HAS3. Int J Biochem Cell Biol (2014) 48:45-54. doi:10.1016/j.biocel.2013.12.016.
74. Okuda H, Kobayashi A, Xia B, Watabe M, Pai SK, Hirota S, et al. Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res (2012) 72(2):537-47. doi:10.1158/0008-5472.CAN-11-1678.
75. Krishnamurthy S, Dong Z, Vodopyanov D, Imai A, Helman JI, Prince ME, et al. Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res (2010) 70(23):9969-78. doi:10.1158/0008-5472.CAN-10-1712.
76. Khammanivong A, Gopalakrishnan R, Dickerson EB. SMURF1 silencing diminishes a CD44-high cancer stem cell-like population in head and neck squamous cell carcinoma. Mol Cancer (2014) 13:260. doi:10.1186/1476-4598-13-260.
77. Shigeishi H, Biddle A, Gammon L, Emich H, Rodini CO, Gemenetzidis E, et al. Maintenance of stem cell self-renewal in head and neck cancers requires actions of GSK3beta influenced by CD44 and RHAMM. Stem Cells (2013) 31(10):2073-83. doi:10.1002/stem.1418.
78. Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, Pinna CM, et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res (2011) 71(13):4640-52. doi:10.1158/0008-5472.CAN-10-3320.
79. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 40(5):499-507. doi:10.1038/ng.127.
80. Wang XQ, Ng RK, Ming X, Zhang W, Chen L, Chu AC, et al. Epigenetic regulation of pluripotent genes mediates stem cell features in human hepatocellular carcinoma and cancer cell lines. PLoS One (2013) 8(9):e72435. doi:10.1371/journal.pone.0072435.
81. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem (2008) 283(25):17635-51. doi:10.1074/jbc.M800109200.
82. Ghatak S, Misra S, Toole BP. Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem (2005) 280(10):8875-83. doi:10.1074/jbc.M410882200.
83. Misra S, Obeid LM, Hannun YA, Minamisawa S, Berger FG, Markwald RR, et al. Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells. J Biol Chem (2008) 283(21):14335-44. doi:10.1074/jbc.M703811200.
84. Lakshman M, Subramaniam V, Rubenthiran U, Jothy S. CD44 promotes resistance to apoptosis in human colon cancer cells. Exp Mol Pathol (2004) 77(1):18-25. doi:10.1016/j.yexmp.2004.03.002.
85. Park YS, Huh JW, Lee JH, Kim HR. shRNA against CD44 inhibits cell proliferation, invasion and migration, and promotes apoptosis of colon carcinoma cells. Oncol Rep (2012) 27(2):339-46. doi:10.3892/or.2011.1532.
86. Fedorchenko O, Stiefelhagen M, Peer-Zada AA, Barthel R, Mayer P, Eckei L, et al. CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia. Blood (2013) 121(20):4126-36. doi:10.1182/blood-2012-11-466250.
87. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev (2002) 16(23):3074-86. doi:10.1101/gad.242602.
88. Jung T, Gross W, Zoller M. CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem (2011) 286(18):15862-74. doi:10.1074/jbc.M110.208421.
89. Yu WH, Woessner JF Jr, McNeish JD, Stamenkovic I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev (2002) 16(3):307-23. doi:10.1101/gad.925702.
90. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem (2009) 284(39):26533-46. doi:10.1074/jbc.M109.027466.
91. Ohashi R, Takahashi F, Cui R, Yoshioka M, Gu T, Sasaki S, et al. Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell. Cancer Lett (2007) 252(2):225-34. doi:10.1016/j.canlet.2006.12.025.
92. Tamada M, Nagano O, Tateyama S, Ohmura M, Yae T, Ishimoto T, et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res (2012) 72(6):1438-48. doi:10.1158/0008-5472.CAN-11-3024.
93. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell (2011) 19(3):387-400. doi:10.1016/j.ccr.2011.01.038.
94. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature (2009) 458(7239):780-3. doi:10.1038/nature07733.
95. Xu Y, Stamenkovic I, Yu Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res (2010) 70(6):2455-64. doi:10.1158/0008-5472.CAN-09-2505.
96. Yasuda M, Tanaka Y, Fujii K, Yasumoto K. CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells. Int Immunol (2001) 13(10):1309-19. doi:10.1093/intimm/13.10.1309.
97. Bollyky PL, Falk BA, Long SA, Preisinger A, Braun KR, Wu RP, et al. CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta. J Immunol (2009) 183(4):2232-41. doi:10.4049/jimmunol.0900191.
98. Akdis CA, Akdis M. Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. J Clin Invest (2014) 124(11):4678-80. doi:10.1172/JCI78891.
99. Kuang DM, Wu Y, Chen N, Cheng J, Zhuang SM, Zheng L. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood (2007) 110(2):587-95. doi:10.1182/blood-2007-01-068031.